Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)

Howard Chertkow, Natalie Phillips, Kenneth Rockwood, Nicole Anderson, Melissa K. Andrew, Robert Bartha, Camille Beaudoin, Nathalie Bélanger, Pierre Bellec, Sylvie Belleville, Howard Bergman, Sarah Best, Jennifer Bethell, Louis Bherer, Sandra Black, Michael Borrie, Richard Camicioli, Julie Carrier, Neil Cashman, Senny ChanLynden Crowshoe, Claudio Cuello, Max Cynader, Thanh Dang-Vu, Samir Das, Roger A. Dixon, Simon Ducharme, Gillian Einstein, Alan C. Evans, Margaret Fahnestock, Howard Feldman, Guylaine Ferland, Elizabeth Finger, John D. Fisk, Jennifer Fogarty, Edward Fon, Ziv Gan-Or, Serge Gauthier, Carol Greenwood, Charlie Henri-Bellemare, Nathan Herrmann, David B. Hogan, Robin Hsiung, Inbal Itzhak, Kristen Jacklin, Krista Lanctôt, Andrew Lim, Ian MacKenzie, Mario Masellis, Colleen Maxwell, Carrie McAiney, Katherine McGilton, Jo Anne McLaurin, Alex Mihailidis, Zia Mohades, Manuel Montero-Odasso, Debra Morgan, Gary Naglie, Haakon Nygaard, Megan O'Connell, Ron Petersen, Randi Pilon, Maria Natasha Rajah, Mark Rapoport, Pamela Roach, Julie M. Robillard, Ekaterina Rogaeva, Pedro Rosa-Neto, Jane Rylett, Joel Sadavoy, Peter St George-Hyslop, Dallas Seitz, Eric Smith, Bojana Stefanovic, Isabelle Vedel, Jennifer D. Walker, Cheryl Wellington, Victor Whitehead, Walter Wittich

Research output: Contribution to journalReview articlepeer-review

Abstract

The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles (2014-2019; 2019-2024) have occurred following peer review, and a third cycle (Phase 3) has just begun. A unique construct was mandated, consisting of 20 national teams in Phase I and 19 teams in Phase II (with research topics spanning from basic to clinical science to health resource systems) along with cross-cutting programs to support them. Responding to the needs of researchers within the CCNA teams, a unique sample of 1173 deeply phenotyped patients with various forms of dementia was accrued and studied over eight years (COMPASS-ND). In the second phase of funding (2019-2024), a national dementia prevention program (CAN-THUMBS UP) was set up. In a short time, this prevention program became a member of the World Wide FINGERS prevention consortium. In this article, the challenges, successes, and impacts of CCNA in Canada and internationally are discussed. Short-term deliverables have occurred, along with considerable promise of impacts in the longer term. The creation of synergy, networking, capacity building, engagement of people with lived experience, and economies of scale have contributed to the considerable success of CCNA by all measures. CCNA is evidence that an organized "centrally-organized" approach to dementia research can catalyze important progress nationally and yield significant and measurable results.

Original languageEnglish (US)
Pages (from-to)535-561
Number of pages27
JournalJournal of Alzheimer's disease : JAD
Volume102
Issue number3
DOIs
StatePublished - Dec 1 2024

Keywords

  • Alzheimer's disease
  • cohort
  • dementia
  • prevention
  • research plan
  • sex
  • synergy

Fingerprint

Dive into the research topics of 'Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)'. Together they form a unique fingerprint.

Cite this